Literature DB >> 621288

Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease.

J Martinez, J E Palascak, D Kwasniak.   

Abstract

To evaluate the possibility that the carbohydrate composition of fibrinogen may be altered in the dysfibrinogenemia associated with liver disease, we studied the sialic acid content of purified fibrinogen from 12 patients with liver disease and its relationship to the prolongation of the thrombin time. Purified fibrinogen showed that Aalpha-, Bbeta-, and gamma-chains when reduced and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and exhibited prolongation of the thrombin time similar to that of the plasma from which it was derived. Sialic acid content of the purified fibrinogen ranged from 12.7 to 71.4% higher in patient fibrinogens when compared to normal controls. A progressive delay in thrombin time was associated with increasing sialic acid content of the patient fibrinogen. Enzymatic removal of sialic acid from four of the abnormal fibrinogens resulted in a shortening of their thrombin times to the range of the desialylated normal control. Periodic acid-Schiff reagent stained only the Bbeta- and gamma-chains of the reduced patient fibrinogens after sodium dodecyl sulfate-polyacrylamide gel electrophoresis suggesting that the excess sialic acid is located on these two chains. These studies demonstrate a biochemical alteration of the functionally abnormal fibrinogen found in some patients with liver disease, and indicate that the excess sialic acid plays an important role in the functional defect of this protein.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 621288      PMCID: PMC372564          DOI: 10.1172/JCI108964

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  The thiobarbituric acid assay of sialic acids.

Authors:  L WARREN
Journal:  J Biol Chem       Date:  1959-08       Impact factor: 5.157

2.  THE PREPARATION AND SOME PROPERTIES OF FIBRINOGEN PRECIPITATED FROM HUMAN PLASMA BY GLYCINE.

Authors:  L A KAZAL; S AMSEL; O P MILLER; L M TOCANTINS
Journal:  Proc Soc Exp Biol Med       Date:  1963 Aug-Sep

3.  Dysfibrinogenemia associated with liver disease.

Authors:  J E Palascak; J Martinez
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

4.  Dysfibrinogenaemia associated with primary hepatoma.

Authors:  R Verhaeghe; B van Damme; A Molla; J Vermylen
Journal:  Scand J Haematol       Date:  1972

5.  Dysfibrinogenemia in a patient with primary hepatoma. First observation of an acquired abnormality of fibrin monomer aggregation.

Authors:  A von Felten; P W Straub; P G Frick
Journal:  N Engl J Med       Date:  1969-02-20       Impact factor: 91.245

6.  The effect of plasmin on the subunit structure of human fibrinogen.

Authors:  S V Pizzo; M L Schwartz; R L Hill; P A McKee
Journal:  J Biol Chem       Date:  1972-02-10       Impact factor: 5.157

7.  [Constitutional and functional differences between glucidic fragments of normal human fibrinogen and an abnormal human fibrinogen].

Authors:  L Mester; L Szabados
Journal:  Bull Soc Chim Biol (Paris)       Date:  1968

8.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

9.  Isolation and characterization of a novel vitamin B12-binding protein associated with hepatocellular carcinoma.

Authors:  R L Burger; S Waxman; H S Gilbert; C S Mehlman; R H Allen
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

10.  Abnormal fibrin polymerization in liver disease.

Authors:  G Green; J M Thomson; I W Dymock; L Poller
Journal:  Br J Haematol       Date:  1976-11       Impact factor: 6.998

View more
  13 in total

Review 1.  Haemostatic problems in liver disease.

Authors:  D A Kelly; E G Tuddenham
Journal:  Gut       Date:  1986-03       Impact factor: 23.059

Review 2.  What Is the Biological and Clinical Relevance of Fibrin?

Authors:  Rustem I Litvinov; John W Weisel
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

3.  Acquired dysfibrinogenaemia masquerading as disseminated intravascular coagulation in acute pancreatitis.

Authors:  J T Wilde; W E Thomas; D A Lane; M Greaves; F E Preston
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

4.  [Glycoproteins: their biological and clinical significance. II (author's transl)].

Authors:  E Köttgen; C Bauer; W Reutter; W Gerok
Journal:  Klin Wochenschr       Date:  1979-03-01

5.  Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation.

Authors:  Y G Kang; D J Martin; J Marquez; J H Lewis; F A Bontempo; B W Shaw; T E Starzl; P M Winter
Journal:  Anesth Analg       Date:  1985-09       Impact factor: 5.108

6.  Fibrinogen measurement in liver disease: validation of the functional fibrinogen thromboelastography assay and a novel mathematical predictive model.

Authors:  Kirsty Rizzo; Kevin Vella; Daniel Zammit; Peter Gatt; Charlie Grima; Monique Borg Inguanez; Jurgen Gerada; Pierre Ellul; Mario Vassallo; Neville Azzopardi; James Pocock; Alex Gatt
Journal:  Blood Transfus       Date:  2018-11-09       Impact factor: 3.443

7.  Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator.

Authors:  H Maekawa; K Yamazumi; S Muramatsu; M Kaneko; H Hirata; N Takahashi; C L Arocha-Piñango; S Rodriguez; H Nagy; J L Perez-Requejo
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

8.  Monitoring coagulation proteins during progression of liver disease.

Authors:  Mohamed Hessien; Mohamed Ayad; Wafaa M Ibrahim; Batoul Izz ulArab
Journal:  Indian J Clin Biochem       Date:  2014-04-19

9.  An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein C-III.

Authors:  G Holdsworth; J Stocks; P Dodson; D J Galton
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

10.  Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy.

Authors:  Nieves Embade; Zoe Mariño; Tammo Diercks; Ainara Cano; Sabela Lens; Diana Cabrera; Miquel Navasa; Juan M Falcón-Pérez; Joan Caballería; Azucena Castro; Jaume Bosch; José M Mato; Oscar Millet
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.